Could Proteon Therapeutics, Inc. (PRTO) Lose its Strength? The Stock Reaches 52-Week High

June 13, 2018 - By Migdalia James

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Logo

Investors sentiment decreased to 0.88 in 2018 Q1. Its down 0.69, from 1.57 in 2017Q4. It fall, as 3 investors sold Proteon Therapeutics, Inc. shares while 5 reduced holdings. 5 funds opened positions while 2 raised stakes. 7.27 million shares or 0.71% more from 7.22 million shares in 2017Q4 were reported.
Citadel Advsr Limited Liability Com reported 18,079 shares. Moreover, Baker Bros Advsrs Ltd Partnership has 0.01% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Abingworth Limited Liability Partnership holds 2.02 million shares. Drw Securities Limited Liability has 0.01% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 53,686 shares. Ra Management Lc holds 1.34M shares. Perceptive Advsr Ltd Llc holds 0.02% or 334,116 shares. Morgan Stanley reported 402 shares. Moreover, Deer Vii And Ltd has 2.94% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Loring Wolcott Coolidge Fiduciary Llp Ma holds 0% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 6,303 shares. Fincl Counselors has invested 0.01% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Boothbay Fund Mgmt Lc has 0.01% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO) for 30,021 shares. Art Advsr Limited owns 12,838 shares. Northern Tru Corporation reported 16,315 shares stake. Panagora Asset Inc owns 15,441 shares for 0% of their portfolio. Acadian Asset Ltd Limited Liability Company accumulated 5,328 shares.

The stock of Proteon Therapeutics, Inc. (NASDAQ:PRTO) hit a new 52-week high and has $2.68 target or 3.00 % above today’s $2.60 share price. The 5 months bullish chart indicates low risk for the $45.95 million company. The 1-year high was reported on Jun, 13 by Barchart.com. If the $2.68 price target is reached, the company will be worth $1.38M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 5.45% or $0.15 during the last trading session, reaching $2.6. About 48,157 shares traded or 43.35% up from the average. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has risen 57.69% since June 13, 2017 and is uptrending. It has outperformed by 45.12% the S&P500.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on August, 6. They expect $-0.33 EPS, 0.00 % or $0.00 from last year’s $-0.33 per share. After $-0.34 actual EPS reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -2.94 % EPS growth.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Ratings Coverage

Among 2 analysts covering Proteon Therapeutics (NASDAQ:PRTO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Proteon Therapeutics had 3 analyst reports since March 15, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Thursday, March 15 by Robert W. Baird. The rating was maintained by H.C. Wainwright on Friday, March 16 with “Hold”. The company was upgraded on Thursday, May 10 by H.C. Wainwright.

Another recent and important Proteon Therapeutics, Inc. (NASDAQ:PRTO) news was published by Seekingalpha.com which published an article titled: “Reader Inquiry: Is Proteon Therapeutics Still A Buy?” on June 11, 2018.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $45.95 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.